Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome

Kröger, N.;Brand, R.;van Biezen, A.;Cahn, J.-Y.;Vannier, J.;et.al.
(2006) Bone Marrow Transplantation — Vol. 37, n° 2, p. 183-189 (2006)

Files

pdfdocument.pdf
  • Restricted Access
  • Adobe PDF
  • 158.58 KB

Details

Authors
  • Kröger, N.
    Author
  • Brand, R.
    Author
  • van Biezen, A.
    Author
  • Cahn, J.-Y.
    Author
  • Ferrant, AugustinUCLouvain
    Author
  • Vannier, J.
    Author
Show more
Abstract
We report the results of 65 patients with treatment-related myelodysplastic syndrome (MDS)/acute myelogenous leukemia (AML) who were transplanted from an autograft and reported to the EBMT. The median age was 39 years (range, 3-69), and stem cell source was bone marrow (n = 31), or peripheral blood progenitor cells (n = 30), or the combination of both (n = 4). The primary disease was solid tumors (n = 37), Hodgkin's disease (n = 13), non-Hodgkin's lymphoma (n = 10), acute lymphoblastic leukemia (n = 2) or myeloproliferative syndromes (n = 3). The types of MDS were as follows: RAEB (n = 1; 2%), RAEB-t (n = 3; 5%), or AML (n = 56; 87%). The median time between diagnosis and transplantation was 5 months (range, 3-86). The Kaplan -Meier estimates of the probability of 3-year overall and disease-free survival were 35% (95% CI: 21-49%) and 32% (95% CI: 18-45%), respectively. The median leukocyte engraftment was faster after transplantation with peripheral blood stem cells than with bone marrow: 12 (range, 9-26) vs 29 (range, 11-67) days (P &lt; 0.001). The cumulative incidence of relapse was 58% (95% CI: 44-72%) and of treatment-related mortality 12% (95% CI: 6-38%). Lower relapse rate was seen in patients transplanted in first complete remission (CR<inf>1</inf> vs non-CR<inf>1</inf>: 3 years: 48 vs 89%; P = 0.05). Furthermore, age beyond 40 years resulted in a higher treatment-related mortality (47 vs 7%; P = 0.01). In a multivariate analysis, transplantation in CR<inf>1</inf> age as well as their interaction influenced overall survival significantly. Autologous transplantation may cure a substantial number of patients with treatment-related MDS/AML, especially if they are in CR<inf>1</inf> and of younger age. © 2006 Nature Publishing Group. All rights reserved.
Affiliations

Citations

Kröger, N., Brand, R., van Biezen, A., Cahn, J.-Y., Slavin, S., Blaise, D., Sierra, J., Zander, A., Niederwieser, D., de Witte, T., Ferrant, A., Messina, C., Narhalakis, N., Björkholm, M., Castel, V., Michallet, M., Gratwohl, A., Barge, R., Heilmann, C., et al. (2006). Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplantation, 37(2), 183-189. https://doi.org/10.1038/sj.bmt.1705226 (Original work published 2006)